ReleaseWire

Global Markets Direct's, 'Staphylococcus Aureus Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Staphylococcus Aureus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections. Staphylococcus Aureus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Global Market Direct's pharmaceuticals report, "Easton Pharmaceuticals Inc. - Product Pipeline Review - 2013" provides data on the Easton Pharmaceuticals Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Corneal Neovascularization - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Corneal Neovascularization, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Corneal Neovascularization. Corneal Neovascularization - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Tillotts Pharma AG - Product Pipeline Review - 2013" provides data on the Tillotts Pharma AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Pharma Two B Ltd - Product Pipeline Review - 2013" provides data on the Pharma Two B Ltd's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Galleon Pharmaceuticals - Product Pipeline Review - 2013" provides data on the Galleon Pharmaceuticals's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "EndoCeutics, Inc. - Product Pipeline Review - 2013" provides data on the EndoCeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "OXiGENE, Inc. - Product Pipeline Review - 2013" provides data on the OXiGENE, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Amicus Therapeutics, Inc. - Product Pipeline Review - 2013" provides data on the Amicus Therapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "SK Biopharmaceuticals Co., Ltd. - Product Pipeline Review - 2013" provides data on the SK Biopharmaceuticals Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "KineMed, Inc. - Product Pipeline Review - 2013" provides data on the KineMed, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Zenotech Laboratories Limited - Product Pipeline Review - 2013" provides data on the Zenotech Laboratories Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Leber Congenital Amaurosis (LCA) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA). Leber Congenital Amaurosis (LCA) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Blood Coagulation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blood Coagulation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Coagulation. Blood Coagulation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Enterococcus Faecium Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. Enterococcus Faecium Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Omeros Corporation - Product Pipeline Review - 2013" provides data on the Omeros Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Bioo Therapeutics - Product Pipeline Review - 2013" provides data on the Bioo Therapeutics's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Arno Therapeutics, Inc. - Product Pipeline Review - 2013" provides data on the Arno Therapeutics, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "ReNeuron Group plc - Product Pipeline Review - 2013" provides data on the ReNeuron Group plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Tauopathies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tauopathies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tauopathies. Tauopathies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Lux Biosciences, Inc. - Product Pipeline Review - 2013" provides data on the Lux Biosciences, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Cardiovascular Inflammation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Inflammation. Cardiovascular Inflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

The global pharmaceuticals and food anti-counterfeiting market is expected to reach USD 160.32 billion by 2030, according to a new study by Grand View Research, Inc. The rise in the consumption of counterfeit products and the implementation of strict regulations pertaining to anti-counterfeiting by the U.S. FDA are two of the primary growth drivers of this market. Moreover, anti-counterfeiting initiatives undertaken by manufacturers to curb revenue and brand image losses, the introduction of technological advancements such as ultra-high RFID tags and the high scale of counterfeiting in rapidly growing economies such as Brazil, India, China and Russia will serve this market as drivers.